Uterine Rescue in High-Risk Gestational Trophoblastic Neoplasia Treated with EMA-CO by Uterine Arteries Embolization due to Arteriovenous Malformations

 

 Permissions and Reprints

Abstract

Complete hydatidiform mole (CHM) is a rare type of pregnancy, in which 15 to 20% of the cases may develop into gestational trophoblastic neoplasia (GTN). The diagnostic of GTN must be done as early as possible through weekly surveillance of serum hCG after uterine evacuation. We report the case of 23-year-old primigravida, with CHM but without surveillance of hCG after uterine evacuation. Two months later, the patient presented to the emergency with vaginal bleeding and was referred to the Centro de Doenças Trofoblásticas do Hospital São Paulo. She was diagnosed with high risk GTN stage/score III:7 as per The International Federation of Gynecology and Obstetrics/World Health Organization (FIGO/WHO). The sonographic examination revealed enlarged uterus with a heterogeneous mass constituted of multiple large vessels invading and causing disarrangement of the myometrium. The patient evolved with progressive worsening of vaginal bleeding after chemotherapy with etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine (EMA-CO) regimen. She underwent blood transfusion and embolization of uterine arteries due to severe vaginal hemorrhage episodes, with complete control of bleeding. The hCG reached a negative value after the third cycle, and there was a complete regression of the anomalous vascularization of the uterus as well as full recovery of the uterine anatomy. The treatment in a reference center was essential for the appropriate management, especially regarding the uterine arteries embolization trough percutaneous femoral artery puncture, which was crucial to avoid the hysterectomy and allow GTN cure and maintenance of reproductive life.

Resumo

Mola hidatiforme completa (MHC) é um tipo raro de gravidez, na qual 15 a 20% dos casos podem desenvolver neoplasia trofoblástica gestacional (NTG). O diagnóstico de NTG deve ser feito o mais cedo possível, pelo monitoramento semanal do hCG sérico após esvaziamento uterino. Relatamos o caso de uma paciente primigesta, de 23 anos de idade, com MHC, sem vigilância de hCG após esvaziamento uterino. Dois meses depois, a paciente compareceu na emergência com sangramento vaginal, sendo encaminhada ao Centro de Doenças Trofoblásticas do Hospital São Paulo, onde foi diagnosticada com NTG de alto risco, estádio e score de risco III:7 de acordo com a The International Federation of Gynecology and Obstetrics/Organização Mundial de Saúde (FIGO/OMS). O exame ultrassonográfico revelou útero aumentado com uma massa heterogênea constituída por múltiplos vasos volumosos invadindo e desestruturando o miométrio. A paciente evoluiu com piora progressiva do sangramento vaginal após quimioterapia com o regime etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine (EMA-CO). Ela foi submetida a transfusão de sangue e embolização das artérias uterinas devido aos episódios graves de hemorragia vaginal, com completo controle do sangramento. O hCG atingiu valor negativo após o terceiro ciclo, havendo regressão completa da vascularização uterina anômala, assim como recuperação da anatomia uterina. O tratamento em um centro de referência permitiu o manejo adequado, principalmente no que se refere à embolização das artérias uterinas através da punção percutânea da artéria femoral, que foi crucial para evitar a histerectomia, permitindo a cura da NTG e a manutenção da vida reprodutiva.

Publication History

Received: 16 July 2020

Accepted: 06 January 2021

Article published online:
12 May 2021

© 2021. Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

• References

• 1 Brown J, Naumann RW, Seckl MJ, Schink J. 15years of progress in gestational trophoblastic disease: Scoring, standardization, and salvage. Gynecol Oncol 2017; 144 (01) 200-207 DOI: 10.1016/j.ygyno.2016.08.330.
  CrossrefPubMedGoogle Scholar
• 2 FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. Int J Gynaecol Obstet 2002; 77 (03) 285-287 DOI: 10.1016/s0020-7292(02)00063-2.
  CrossrefPubMedGoogle Scholar
• 3 Ngan HYS, Seckl MJ, Berkowitz RS. et al. Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynaecol Obstet 2018; 143 (Suppl. 02) 79-85 DOI: 10.1002/ijgo.12615.
  CrossrefPubMedGoogle Scholar
• 4 Braga A, Lima L, Parente RCM. et al. Management of symptomatic uterine arteriovenous malformations after gestational trophoblastic disease. The Brazilian experience and possible role for depot medroxyprogesterone acetate and tranexamic acid treatment. J Reprod Med 2018; 63 (5–6): 228-239
  PubMedGoogle Scholar
• 5 Lim AKP, Agarwal R, Seckl MJ, Newlands ES, Barrett NK, Mitchell AWM. Embolization of bleeding residual uterine vascular malformations in patients with treated gestational trophoblastic tumors. Radiology 2002; 222 (03) 640-644 DOI: 10.1148/radiol.2223010035.
  CrossrefPubMedGoogle Scholar
• 6 Seckl MJ, Sebire NJ, Fisher RA, Golfier F, Massuger L, Sessa C. ESMO Guidelines Working Group. Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl. 06) vi39-vi50 DOI: 10.1093/annonc/mdt345.
  CrossrefPubMedGoogle Scholar
• 7 Sun SY, Melamed A, Joseph NT. et al. Clinical presentation of complete hydatidiform mole and partial hydatidiform mole at a regional trophoblastic disease center in the United States over the past 2 decades. Int J Gynecol Cancer 2016; 26 (02) 367-370 DOI: 10.1097/IGC.0000000000000608.
  CrossrefPubMedGoogle Scholar
• 8 Padrón L, Rezende Filho J, Amim Junior J. et al. Manual compared with electric vacuum aspiration for treatment of molar pregnancy. Obstet Gynecol 2018; 131 (04) 652-659 DOI: 10.1097/AOG.0000000000002522.
  CrossrefPubMedGoogle Scholar
• 9 Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet 2010; 376 (9742): 717-729 DOI: 10.1016/S0140-6736(10)60280-2.
  CrossrefPubMedGoogle Scholar
• 10 Dantas PRS, Maestá I, Cortés-Charry R. et al. Influence of hydatidiform mole follow-up setting on postmolar gestational trophoblastic neoplasia outcomes: a cohort study. J Reprod Med 2012; 57 (7-8): 305-309
  PubMedGoogle Scholar
• 11 Quinn M, Murray J, Friedlander M. et al. EMACO in high risk gestational trophoblast disease--the Australian experience. Gestational Trophoblast Subcommittee, Clinical Oncological Society of Australia. Aust N Z J Obstet Gynaecol 1994; 34 (01) 90-92 DOI: 10.1111/j.1479-828x.1994.tb01047.x.
  CrossrefPubMedGoogle Scholar
• 12 Tranoulis A, Georgiou D, Sayasneh A, Tidy J. Gestational trophoblastic neoplasia: a meta-analysis evaluating reproductive and obstetrical outcomes after administration of chemotherapy. Int J Gynecol Cancer 2019; 29 (06) 1021-1031 DOI: 10.1136/ijgc-2019-000604.
  CrossrefPubMedGoogle Scholar
• 13 Torre A, Fauconnier A, Kahn V, Limot O, Bussierres L, Pelage JP. Fertility after uterine artery embolization for symptomatic multiple fibroids with no other infertility factors. Eur Radiol 2017; 27 (07) 2850-2859 DOI: 10.1007/s00330-016-4681-z.
  CrossrefPubMedGoogle Scholar
• 14 Touhami O, Gregoire J, Noel P, Trinh XB, Plante M. Uterine arteriovenous malformations following gestational trophoblastic neoplasia: a systematic review. Eur J Obstet Gynecol Reprod Biol 2014; 181: 54-59 DOI: 10.1016/j.ejogrb.2014.07.023.
  CrossrefPubMedGoogle Scholar
• 15 Braga A, Mora P, de Melo AC. et al. Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide. World J Clin Oncol 2019; 10 (02) 28-37 DOI: 10.5306/wjco.v10.i2.28.
  CrossrefPubMedGoogle Scholar
• 16 Belfort P, Braga A, Freire NS. [Uterine arteriovenous malformation after gestational trophoblastic disease]. Rev Bras Ginecol Obstet 2006; 28 (02) 112-121 DOI: 10.1590/S0100-72032006000200007. Portuguese.
  CrossrefPubMedGoogle Scholar